Colorectal Cancer | Specialty

The OncLive Colorectal Cancer condition center page is a comprehensive resource for clinical news and expert insights on colorectal cancer treatment and management, with a focus on novel therapeutic strategies including checkpoint inhibitors and TKIs across lines of therapy. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in colorectal cancer.

Overcoming Challenges in the Management of mCRC

February 8th 2019

Later-Line Treatment for mCRC: Regorafenib or TAS-102?

February 8th 2019

mCRC: Stratifying Patients to Appropriate Therapy

February 8th 2019

Improving Molecular Understandings of mCRC

February 8th 2019

Metastatic Colorectal Cancer: Frontline Treatment Paradigm

February 8th 2019

Future of CRC Rests in Greater Genomic Understanding

February 7th 2019

Marwan Fakih, MD, discusses recent trials in colorectal cancer and highlights other ongoing research in the field.

Dr. Kasi on the Application of Pharmacogenomics in CRC

February 5th 2019

Pashtoon M. Kasi, MD, MBBS, MS, assistant professor of oncology and senior associate consultant in the Division of Hematology/Oncology at Mayo Clinic, discusses the application of pharmacogenomics in colorectal cancer (CRC).

Online Tool Estimates the Risk for Lynch Syndrome

February 5th 2019

Because specific risk-reducing interventions may be available, it is important to identify individuals with germline variants in cancer susceptibility genes.

Expert Discusses CRC Developments, Importance of Molecular Profiling

February 4th 2019

Pashtoon M. Kasi, MD, MBBS, MS, provides an overview of the potential for liquid biopsies in CRC and advances being made in the treatment landscape.

Overcoming Acquired Resistance Mechanisms in BRAF+ mCRC

January 31st 2019

First-Line Triplet in BRAF+ mCRC

January 31st 2019

Real-World Management of Patients with BRAF-V600E mCRC

January 31st 2019

CRC Safety Lead-in: ASCO GI 2019 Updates

January 31st 2019

Combining BRAF, MEK and EGFR Inhibition in mCRC

January 31st 2019

Lack of Durable Responses in Current Treatment of mCRC

January 31st 2019

Sequencing Strategies in BRAF-Mutated mCRC

January 31st 2019

Prognosticating BRAF-Mutant mCRC

January 31st 2019

Dr. Fakih on Durvalumab and Tremelimumab in CRC

January 31st 2019

Marwan Fakih, MD, professor, Department of Medical Oncology and Therapeutics Research, associate director for Clinical Investigations, Comprehensive Cancer Center, medical director, Judy and Bernard Briskin Center for Clinical Research, co-director, Gastrointestinal Cancer Program, and section head, Gastrointestinal Medical Oncology, City of Hope, discusses the combination of durvalumab (Imfinzi) and tremelimumab in patients with metastatic colorectal cancer (mCRC).

Immune-Oncology Role Continues to Be Refined in GI Cancer

January 28th 2019

Michael J. Overman, MD, highlights new combination agents under investigation for the treatment of patients with GI cancers—specifically CRC—and challenges that still need to be addressed.

Dr. Shields Discusses Patient Selection Criteria for Adjuvant Therapy in CRC

January 25th 2019

Anthony Shields, MD, PhD, oncologist, Department of Oncology, Molecular Imaging and Diagnostics Program, Karmanos Cancer Institute, discusses patient selection criteria for adjuvant therapy in colorectal cancer (CRC).